Opinion: Healthcare professional supports FDA’s proposal to end sale of menthol cigarettes, flavored cigars

After decades of public health campaigns, we all know the toll that smoking takes on our health, but I see the addiction and disease associated with tobacco use in my office every day. As a nurse, I work with people who struggle with addiction to tobacco and are living with the diseases that tobacco causes.

Therefore, I am urging the U.S. FDA (U.S. Food and Drug Administration) to finalize its proposed rules to end the sale of menthol cigarettes and flavored cigars as soon as possible.

It is estimated that nationally, one-third of all people who smoke, use menthol cigarettes – a total of 18.9 million people. And the health impacts of menthol cigarettes are not equally shared among communities in the U.S. The tobacco industry has targeted their marketing for menthol cigarettes specifically to certain racial/ethnic groups, especially Black Americans, since the 1950s. The industry has also marketed menthol cigarettes extensively to the LGBTQ community. This has resulted in significant smoking-related health disparities among Black and LGBTQ+ (Lesbian, Gay, Bisexual, Transgender and Queer) Americans.

Menthol cigarettes make it easier to start smoking and harder to quit, so removing menthol cigarettes from the market will be a pivotal moment to motivate people to quit for good. In fact, in the first 13-17 months of removing menthol cigarettes from the marketplace, one study estimates 923,000 smokers would quit. And we know what works to help people quit— a combination of FDA-approved cessation medication plus proven-effective behavioral counseling programs, such as Freedom From Smoking.

I urge my fellow healthcare professionals to speak up in support of the FDA’s proposed rules to end the sale of menthol cigarettes and flavored cigars. Join me and the American Lung Association to speak up at Lung.org/ActonMenthol.

 

Amita Avadhani

Ph.D., DNP, NEA-BC, CNE, DCC, ACNP-BC, NP-C, CCRN, FAANP, FCCM

Director, Post Masters DNP-Practice (Executive Weekend Model)

Professor-Clinical, Advance Practice Division, School of Nursing

Rutgers Biomedical & Health Sciences (RBHS) Rutgers, The State University of New Jersey

South Brunswick